ML Disis

816 total citations
20 papers, 699 citations indexed

About

ML Disis is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, ML Disis has authored 20 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 10 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in ML Disis's work include Immunotherapy and Immune Responses (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). ML Disis is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). ML Disis collaborates with scholars based in United States. ML Disis's co-authors include H. Bernhard, JR Gralow, Steven Gillis, Julie R. Gralow, Susan L. Hand, Martin A. Cheever, Jennifer S. Childs, Robert A. Figlin, John H. Strickler and John Fikes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

ML Disis

19 papers receiving 688 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
ML Disis United States	7	579	264	229	184	70	20	699
Antonio Scardino France	15	608 1.1×	362 1.4×	183 0.8×	89 0.5×	100 1.4×	18	758
Konstadinos Kosmatopoulos France	8	520 0.9×	205 0.8×	94 0.4×	79 0.4×	91 1.3×	13	637
Jordana Griffiths United Kingdom	6	413 0.7×	147 0.6×	125 0.5×	193 1.0×	70 1.0×	6	684
Adam Gulbranson‐Judge United Kingdom	14	1.5k 2.5×	164 0.6×	177 0.8×	104 0.6×	72 1.0×	17	1.7k
Gemma Pidelaserra-Martí Germany	6	349 0.6×	129 0.5×	135 0.6×	149 0.8×	36 0.5×	7	630
Yanal Murad Canada	14	209 0.4×	226 0.9×	166 0.7×	106 0.6×	97 1.4×	26	583
Michelle Attaya United States	6	926 1.6×	334 1.3×	143 0.6×	122 0.7×	94 1.3×	7	1.1k
Mark H. Fogg United States	14	291 0.5×	270 1.0×	277 1.2×	174 0.9×	187 2.7×	26	767
Nadine Bizouarne France	12	567 1.0×	407 1.5×	338 1.5×	134 0.7×	89 1.3×	17	834
Peter Molloy United Kingdom	10	524 0.9×	238 0.9×	483 2.1×	221 1.2×	61 0.9×	18	808

Countries citing papers authored by ML Disis

Since Specialization

Citations

This map shows the geographic impact of ML Disis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by ML Disis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites ML Disis more than expected).

Fields of papers citing papers by ML Disis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by ML Disis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by ML Disis. The network helps show where ML Disis may publish in the future.

Co-authorship network of co-authors of ML Disis

This figure shows the co-authorship network connecting the top 25 collaborators of ML Disis. A scholar is included among the top collaborators of ML Disis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with ML Disis. ML Disis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Disis, ML, et al.. (2017). Abstract OT3-01-03: A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer. Cancer Research. 77(4_Supplement). OT3–1. 7 indexed citations

2.

Higgins, Doreen M., et al.. (2016). Abstract P2-11-03: Phase I/II randomized study of combination immunotherapy with or without polysaccharide krestin (PSK) concurrently with a HER2 ICD peptide-based vaccine in patients with stage IV breast cancer receiving HER2-targeted monoclonal antibody therapy. Cancer Research. 76(4_Supplement). P2–11. 2 indexed citations

3.

Disis, ML, et al.. (2016). Abstract OT1-01-01: A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients. Cancer Research. 76(4_Supplement). OT1–1. 7 indexed citations

4.

Disis, ML, E.P. Hamilton, A. Craig Lockhart, et al.. (2015). 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. European Journal of Cancer. 51. S546–S547. 9 indexed citations

5.

Lu, Hai, et al.. (2012). Abstract OT3-1-02: Phase II randomized study of combination immunotherapy with or without Polysaccharide Krestin (PSK®) concurrently with a HER2 ICD peptide-based vaccine and trastuzumab in patients with stage IV breast cancer. Cancer Research. 72(24_Supplement). OT3–1. 2 indexed citations

6.

Childs, Jennifer S., et al.. (2011). OT1-02-10: Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients.. Cancer Research. 71(24_Supplement). OT1–2. 1 indexed citations

7.

Swensen, Ron E., Jennifer S. Childs, Doreen M. Higgins, et al.. (2011). A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.. Journal of Clinical Oncology. 29(15_suppl). 5020–5020. 1 indexed citations

8.

Gray, Heidi J., et al.. (2011). P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases.. Cancer Research. 71(24_Supplement). P1–13. 1 indexed citations

9.

Salazar, Lupe G., Ron E. Swensen, Andrew L. Coveler, et al.. (2008). Phase I study of intraperitoneal (IP) denileukin diftitox in patients with advanced ovarian cancer (OC). Journal of Clinical Oncology. 26(15_suppl). 3036–3036. 2 indexed citations

10.

Disis, ML, John H. Strickler, Danelle R. Wallace, et al.. (2008). Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine. Journal of Clinical Oncology. 26(15_suppl). 3015–3015. 7 indexed citations

11.

Emens, Leisha A., Justin M. Asquith, James M. Leatherman, et al.. (2008). Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine. Journal of Clinical Oncology. 26(15_suppl). 3009–3009. 1 indexed citations

12.

Disis, ML, Saul E. Rivkin, Andre T. Baron, et al.. (2006). Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium. International Journal of Gynecological Cancer. 16(2). 463–469. 2 indexed citations

13.

Disis, ML, Saul E. Rivkin, Andre T. Baron, et al.. (2006). Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium. International Journal of Gynecological Cancer. 16(2). 463–469. 1 indexed citations

14.

Disis, ML. (2005). 1–33 Fusion Cell Vaccination of Patients With Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. Breast Diseases A Year Book Quarterly. 16(1). 65–66. 4 indexed citations

15.

Ishioka, Glenn, ML Disis, Michael A. Morse, et al.. (2004). A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. Journal of Clinical Oncology. 22(14_suppl). 2525–2525. 3 indexed citations

16.

Ishioka, Glenn, ML Disis, Michael A. Morse, et al.. (2004). A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. Journal of Clinical Oncology. 22(14_suppl). 2525–2525. 2 indexed citations

17.

Disis, ML, Vivian Goodell, Ling-Yu Kuan, et al.. (2004). Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation. Journal of Immunotherapy. 27(6). S40–S40. 2 indexed citations

18.

Disis, ML, et al.. (1996). Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. The Journal of Immunology. 156(9). 3151–3158. 158 indexed citations

19.

Disis, ML, et al.. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 88(1). 202–210. 260 indexed citations

20.

Disis, ML, et al.. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 88(1). 202–210. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact